In a move to allay antitrust concerns, GlaxoSmithKline is selling two of its meningitis vaccines to Big Pharma peer Pfizer. The move comes after Glaxo acquired the bulk of Novartis' vaccines portfolio, which catapulted it to the No. 1 spot in the global vaccines market.
Anyone expecting one vaccines maker to pull away from the pack by 2020 had better reconsider. The top four companies--Merck, GlaxoSmithKline, Sanofi and Pfizer--are expected to be within less than one percentage point of each other in total market share, a new report says. Read more >>
If Merck has answers regarding the efficacy of its mumps vaccine, it's not being forthright, says a letter filed by an attorney representing two former Merck virologists who are now whistleblowers. Read more >>
POPULAR COMMENT THREADS
The CDC's Advisory Committee on Immunization Practices (ACIP) voted on Wednesday to expand its recommendation for meningitis B vaccines, but it wasn't the broad recommendation that many were hoping to see.
After suffering a Phase III immunotherapy flop in 2013 and restructuring, Vical delivered another piece of damaging news on Monday that sent the company's shares into penny stock territory.
As the MERS outbreak in South Korea continues to unfold, scientists at Ludwig Maximilian University of Munich are ushering a candidate vaccine into clinical trials with hopes of a winner.
After publishing promising preclinical results, a team from the Scripps Research Institute, led by researcher William Schief, are taking their HIV vaccine candidate to federal regulators to discuss human trials.
The National Institutes of Health has awarded Northeastern professor of chemical engineering Shashi Murthy a four-year $1.4 million grant to develop a novel instrument that would ease a "tremendous bottleneck" in vaccine development.
The race for an Ebola vaccine has slowed to a crawl as Big Pharmas GlaxoSmithKline, Merck and Johnson & Johnson struggle to find volunteers who are exposed to enough disease to show whether experimental vaccines actually protect against Ebola infection.
From Our Sister Sites
Consultants tell Reuters that large Indian companies are heeding the warnings from regulators and investing more in equipment and training. But some small to medium-sized companies are considering whether to pour money into their operations, retreat from high-profit but regulatory-heavy markets like the U.S. and Europe, or cash out.
India's Dr. Reddy's Laboratories is having to recall both an epilepsy drug and a combo cardiovascular drug all made in India. One, the FDA says, is too strong while the other is not strong enough. The recalls come even as the FDA has been paying special attention to generic equivalence after testing has found evidence that some generics are not measuring up.